Intuitive Surgical (NASDAQ:ISRG) Price Target Raised to $421.00 at BTIG Research

Intuitive Surgical (NASDAQ:ISRG) had its target price boosted by equities researchers at BTIG Research from $412.00 to $421.00 in a report issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. BTIG Research’s target price would indicate a potential upside of 14.72% from the stock’s current price.

Several other analysts have also recently weighed in on ISRG. Piper Sandler lifted their price objective on Intuitive Surgical from $325.00 to $425.00 and gave the company an “overweight” rating in a research report on Wednesday, January 24th. Citigroup lifted their target price on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. StockNews.com lowered shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Barclays lifted their target price on shares of Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a report on Thursday, January 25th. Finally, Robert W. Baird decreased their price objective on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a report on Friday. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $381.24.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG traded down $5.65 during trading hours on Friday, hitting $366.98. The company’s stock had a trading volume of 2,439,928 shares, compared to its average volume of 1,654,617. The stock has a market cap of $130.08 billion, a price-to-earnings ratio of 73.65, a P/E/G ratio of 5.81 and a beta of 1.36. Intuitive Surgical has a 12 month low of $254.85 and a 12 month high of $403.76. The business has a 50-day simple moving average of $387.27 and a 200-day simple moving average of $342.60.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.10. The company had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a return on equity of 13.11% and a net margin of 25.24%. Intuitive Surgical’s quarterly revenue was up 11.5% on a year-over-year basis. During the same period last year, the firm earned $1.00 earnings per share. On average, equities research analysts forecast that Intuitive Surgical will post 4.93 EPS for the current year.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the completion of the transaction, the vice president now owns 26,877 shares of the company’s stock, valued at approximately $10,349,795.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, VP Marshall Mohr sold 108,790 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the sale, the vice president now directly owns 26,877 shares in the company, valued at approximately $10,349,795.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Myriam Curet sold 4,318 shares of the company’s stock in a transaction dated Friday, January 26th. The shares were sold at an average price of $370.15, for a total transaction of $1,598,307.70. Following the sale, the executive vice president now owns 189 shares in the company, valued at $69,958.35. The disclosure for this sale can be found here. Insiders sold 248,418 shares of company stock valued at $95,927,097 in the last 90 days. Insiders own 0.90% of the company’s stock.

Institutional Trading of Intuitive Surgical

Several hedge funds have recently made changes to their positions in the business. RB Capital Management LLC raised its position in Intuitive Surgical by 4.4% in the 1st quarter. RB Capital Management LLC now owns 1,735 shares of the medical equipment provider’s stock worth $523,000 after purchasing an additional 73 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Intuitive Surgical by 0.6% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 946,709 shares of the medical equipment provider’s stock valued at $285,603,000 after purchasing an additional 5,233 shares in the last quarter. Baird Financial Group Inc. boosted its stake in shares of Intuitive Surgical by 2.3% during the first quarter. Baird Financial Group Inc. now owns 21,089 shares of the medical equipment provider’s stock valued at $6,362,000 after purchasing an additional 481 shares in the last quarter. Brown Brothers Harriman & Co. boosted its stake in shares of Intuitive Surgical by 576.7% during the first quarter. Brown Brothers Harriman & Co. now owns 406 shares of the medical equipment provider’s stock valued at $122,000 after purchasing an additional 346 shares in the last quarter. Finally, Covestor Ltd boosted its stake in shares of Intuitive Surgical by 50.4% during the first quarter. Covestor Ltd now owns 418 shares of the medical equipment provider’s stock valued at $126,000 after purchasing an additional 140 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.